Anzeige
Mehr »
Mittwoch, 29.10.2025 - Börsentäglich über 12.000 News
Die 80-Milliarden-Dollar-Nuklear-Renaissance: Warum Uran der heißeste Sektor der Welt ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCUH | ISIN: SE0014855029 | Ticker-Symbol: 8IM1
Tradegate
28.10.25 | 18:36
5,160 Euro
-0,77 % -0,040
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMPLANTICA AG SDR Chart 1 Jahr
5-Tage-Chart
IMPLANTICA AG SDR 5-Tage-Chart
RealtimeGeldBriefZeit
4,8954,97017:02
4,8954,97017:02

Aktuelle News zur IMPLANTICA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoImplantica presents the third quarter 2025 on October 31 at 15:00 CET161VADUZ, Liechtenstein, Oct. 27, 2025 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the third quarter 2025 at 15:00 CET on October 31. The interim report...
► Artikel lesen
13.10.Implantica completes FDA 100-Day Meeting for RefluxStop PMA application235VADUZ, Liechtenstein, Oct. 13, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative...
► Artikel lesen
06.10.Implantica Successfully Completes MDSAP Recertification Audit237VADUZ, Liechtenstein, Oct. 6, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative...
► Artikel lesen
IMPLANTICA Aktie jetzt für 0€ handeln
25.09.Implantica steps up to close the treatment gap with RefluxStop as main device competitor exits Europe and the UK333VADUZ, Liechtenstein, Sept. 25, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device...
► Artikel lesen
24.09.Implantica announces U.S. FDA has provided feedback on the final RefluxStop PMA submission, Module 3283VADUZ, Liechtenstein, Sept. 24, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device...
► Artikel lesen
17.09.Implantica's RefluxStop sparks strong excitement at the American Foregut Society meeting, ahead of pending US FDA approval356VADUZ, Liechtenstein, Sept. 17, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop®...
► Artikel lesen
10.09.Implantica announces the payment of share rewards based on the AGM approved share-based incentive program as a directed share issue of own shares of the company without consideration6
10.09.Implantica ramps-up production with 10,000 RefluxStop units in preparation for U.S. launch, pending FDA PMA approval293VADUZ, Liechtenstein, Sept. 10, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop®...
► Artikel lesen
14.08.Implantica publishes Interim Report January - June 2025 (Q2)380VADUZ, Liechtenstein, Aug. 14, 2025 /PRNewswire/ -- Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 FDA...
► Artikel lesen
13.08.Implantica finishes new multi-cavity production tool for RefluxStop to support manufacturing ramp-up in the U.S. pending FDA approval341VADUZ, Liechtenstein, Aug. 13, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop®...
► Artikel lesen
07.08.Implantica presents the second quarter 2025 on August 14 at 15:00 CEST266VADUZ, Liechtenstein, Aug. 7, 2025 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the second quarter 2025 at 15:00 CEST on August 14. The interim report for the...
► Artikel lesen
07.08.Implantica announces second publication of groundbreaking 5-year results from the landmark RefluxStop clinical study334VADUZ, Liechtenstein, Aug. 7, 2025 /PRNewswire/ -- Implantica AG (publ), a leading medtech company pioneering advanced implantable medical technologies, today announced the second peer-reviewed...
► Artikel lesen
01.07.Implantica announces publication of the landmark RefluxStop 5-year clinical study results demonstrating excellent long-term success360VADUZ, Liechtenstein, July 1, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device RefluxStop®, a treatment field...
► Artikel lesen
24.06.Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop for US market approval427VADUZ, Liechtenstein, June 24, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device...
► Artikel lesen
17.06.Implantica announces successful UK RefluxStop Users Meeting addressing growing demand after the final and positive UK NICE recommendations on use of RefluxStop in NHS public hospitals390VADUZ, Liechtenstein, June 17, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of treatment for acid reflux with its unique device RefluxStop, a treatment field...
► Artikel lesen
12.06.Implantica announces new real-world Swiss study on 99 RefluxStop patients comparing small and large hiatal hernia, confirming equally excellent long-term results309VADUZ, Liechtenstein, June 12, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device...
► Artikel lesen
04.06.Implantica announces that UK NICE has published positive recommendations for the RefluxStop procedure in the NHS public hospitals377VADUZ, Liechtenstein, June 4, 2025 /PRNewswire/ -- Implantica AG (publ.), providing the unique device RefluxStop for the treatment of acid reflux, announces that the world-renowned National...
► Artikel lesen
27.05.Implantica's RefluxStop stimulates intensive dialogue at DDW, the world's largest Digestive Disease conference, held in the U.S.522VADUZ, Liechtenstein, May 27, 2025 /PRNewswire/ -- Implantica AG (publ.) reports successful pre-launch activities in the U.S., pending FDA approval, with European real-world clinical evidence...
► Artikel lesen
15.05.Bulletin from the Annual General Meeting of Implantica AG383VADUZ, Liechtenstein, May 15, 2025 /PRNewswire/ -- Today, May 15, 2025, the annual general meeting (the "AGM") of Implantica AG (publ) was held in Ruggell, Liechtenstein. The general meeting...
► Artikel lesen
09.05.Implantica publishes Interim Report January - March 2025 (Q1)440VADUZ, Liechtenstein, May 9, 2025 /PRNewswire/ -- Global expansion of RefluxStop Significant events in the first quarter of 2025 Received positive feedback from U.S. FDA on...
► Artikel lesen
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1